FDA Now Requires A NAION Warning On Every GLP-1 Drug: What It Means For Plaintiffs In MDL 3163

On November 9, 2026, FDA issued a Drug Safety Communication requiring application holders for all GLP-1 receptor agonist medications to add non-arteritic anterior ischemic optic neuropathy — NAION, a form of sudden and usually permanent vision loss — to the Warnings and Precautions section of their labeling….
By: Marin & Murphy Law Firm